logo
Marijuana is not harmless. The opposite is true and the evidence keeps growing

Marijuana is not harmless. The opposite is true and the evidence keeps growing

Fox News4 days ago
PROGRAMMING ALERT: Watch author Alex Berenson discuss this topic and more on Fox News Channel's "Fox & Friends" on July 1 at 7: 30 am.
The news about marijuana keeps getting worse.
As drug advocates pushed marijuana legalization over the last 15 years, they portrayed the drug as harmless, a mild intoxicant with few side effects. Cannabis – the term scientists prefer for marijuana – might even have medicinal value, advocates said.
The truth is the opposite.
Even in states, from Maine to California, that have legalized cannabis, researchers have published paper after paper showing its risks, particularly to heavy or daily users. I do not mean the munchies or falling asleep on the couch. Powerful evidence links the drug to heart attacks, strokes, severe mental illness, and even suicides.
Cannabis and its active ingredient, the chemical called THC, are toxic to the heart and brain. They are also much more addictive than many users realize. Though cannabis does not cause the physical dependence of alcohol, it can make users psychologically dependent, leading to irritability, depression, and mood swings if they cut back. And a huge new study shows that legalization is linked to a sharp increase in diagnoses of cannabis addiction.
As more Americans see the problems firsthand, their views of cannabis are slowly turning negative, a recent Gallup poll found. Even in deep-blue New York, almost twice as many residents say cannabis legalization has hurt their quality of life as helped it.
But just as it took decades for the public to realize the cancer risks of cigarettes, the health harms of cannabis are not completely understood. A majority of Americans still favor legalization – a fact that makes the emerging science even more alarming.
In March, scientists in Boston reported cannabis users under 50 had a sixfold higher risk of heart attacks compared to people who didn't. In February, Canadian researchers found people hospitalized with a diagnosis of cannabis abuse were six times as likely to die as the average person over the next five years. Suicides and trauma-related deaths made up much of the increase.
The research on the psychiatric harms of cannabis is also piling up.
The connection between cannabis and severe mental illness, including the psychotic disorder schizophrenia, comes as no surprise to me. In 2019, I wrote the book "Tell Your Children: The Truth About Marijuana, Mental Illness, and Violence." At the time, drug legalizers and their media handmaidens sharply criticized the book. The Guardian, a leftist British newspaper, called it "pure alarmism."
Six years later, "Tell Your Children" has been vindicated. In April, researchers in Quebec found a crucial mechanism in the brain by which cannabis can cause hallucinations and delusions.. And just weeks ago, physicians in Colorado – the first state to legalize cannabis – reported that diagnoses of psychosis in young people have soared in the last 15 years, with diagnoses in heavy cannabis users driving the increase.
The science is clear.
Even for adults, cannabis isn't safe, especially for daily use. For teens, whose brains are still developing, it is highly risky – and at worst can lead to lifelong psychiatric problems. It is addictive.
It is far more potent than a generation ago, and THC, its active ingredient, is now available in brightly colored gummies and other "edibles" that are the leading cause of poisonings in young children.
As The New York Times itself admitted last year:
As marijuana legalization spreads across the country, people are consuming more of the drug, more often and at ever-higher potencies… a growing number, mainly heavy users, have experienced addiction, psychosis and other harmful effects…
Meanwhile, the promises of cannabis legalization have not come true. Tax revenue from legal cannabis is a rounding error in state budgets, and legalization has not ended the illegal market in cannabis, which remains large and violent. If anything, legal stores are actually losing ground to illegal dealers at this point.
The core reason is that legal sellers face regulations, taxes, and insurance costs that illegal sellers do not. Illegal sellers can undercut the legal price. And the heavy users who buy most cannabis want the lowest price, legal or not.
Thirteen years after Colorado became the first state to legalize recreational cannabis, the experiment has failed. But powerful economic forces and the media's refusal to admit what's really going on mean that most Americans don't know the truth yet.
Eventually, they will.
In the meantime, Tell Your Children – cannabis is far from benign.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Yahoo

time42 minutes ago

  • Yahoo

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

Yahoo

time2 hours ago

  • Yahoo

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments
Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Yahoo

time2 hours ago

  • Yahoo

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Waystar Holding Corp. (NASDAQ:WAY) is one of the best new stocks to buy now. On June 23, Waystar announced the findings of a commissioned study conducted by Forrester Consulting. The study is titled 'AI in Healthcare Payments Software: A Strategic Imperative,' and revealed that AI is becoming increasingly critical in revenue cycle management/RCM due to its proven impact and measurable ROI. The research shows acceleration in AI adoption within healthcare. 82% of healthcare leaders now consider AI an integral part of their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering improvements in key revenue cycle metrics, such as a 13% to 37% improvement in high-impact areas such as claim accuracy, denial prevention, workforce efficiency, and payment speed. A medical professional with a patient explaining the effects of neurostimulation treatments. Trust in AI is growing, with 60% of decision-makers reporting increased confidence since implementing AI. ~ 70% of healthcare leaders view AI as a high or critical organizational priority, and 60% plan to increase their AI investment. The study is based on responses from 300+ healthcare leaders and highlights a preference for existing RCM software partners when it comes to AI capabilities. Waystar serves ~30,000 clients and represents over 1 million distinct providers, including 16 of the top 20 institutions on the US News Best Hospitals list. Waystar Holding Corp. (NASDAQ:WAY) develops a cloud-based software solution for healthcare payments. While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store